

**France Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous, Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House, Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F**

Market Report | 2023-11-07 | 78 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

**Report description:**

France Cell Therapy Manufacturing Market is anticipated to project impressive growth in the forecast period. The cell therapy manufacturing market in France is experiencing significant growth, driven by advancements in biotechnology and an increasing focus on personalized medicine. Key players in the industry are investing heavily in research and development, aiming to bring innovative cell therapies to the market.

**Key Market Drivers**

**Technological Advancements**

In the ever-evolving landscape of healthcare, technological advancements play a pivotal role in shaping the trajectory of industries, and cell therapy manufacturing is no exception. France, at the forefront of this scientific revolution, is witnessing a surge in growth, driven by innovative technologies that are transforming the way cell therapies are developed and manufactured. One of the key technological drivers behind the growth of the cell therapy manufacturing market in France is the integration of automation into production processes. Automated systems streamline manufacturing, reducing the risk of errors and enhancing

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

overall efficiency. From cell culture to harvesting and processing, automation accelerates production timelines, ensures consistency, and significantly reduces costs, contributing to the market's expansion.

Technological advancements in bioreactor systems have revolutionized the scalability and reproducibility of cell therapy manufacturing. France has embraced these sophisticated systems that provide optimal conditions for cell growth, leading to higher yields and improved product quality. The adoption of advanced bioreactor technologies enables the production of large quantities of cells, meeting the increasing demand for cell therapies in a cost-effective manner.

Closed-system processing is another technological innovation driving growth in the French cell therapy manufacturing market. These systems prevent contamination and maintain sterility throughout the production process, ensuring the integrity of cell-based therapies. The use of closed systems not only improves the safety and quality of the final product but also simplifies manufacturing workflows, reducing the risk of cross-contamination and enhancing overall efficiency.

Technological advancements enable real-time monitoring and control of critical parameters during cell therapy manufacturing. Continuous monitoring of variables such as temperature, pH, and nutrient levels ensures that cells are cultivated under optimal conditions. This level of control enhances the reproducibility of manufacturing processes, resulting in more consistent and reliable cell therapies.

The integration of data analytics and artificial intelligence (AI) is transforming how data is processed and utilized in cell therapy manufacturing. These technologies analyze complex datasets, identify patterns, and optimize manufacturing processes in real-time. In France, leveraging AI in cell therapy manufacturing not only improves the efficiency of operations but also contributes to predictive modeling, enabling better decision-making and reducing the time-to-market for innovative therapies.

#### Investments in Research and Development

In the dynamic realm of healthcare, cell therapy is emerging as a revolutionary approach for treating a myriad of diseases. In France, the cell therapy manufacturing market is experiencing robust growth, with investments in research and development (R&D) playing a pivotal role.

Investments in R&D fuel scientific exploration, leading to breakthroughs that redefine the landscape of cell therapy manufacturing. France's commitment to funding cutting-edge research enables scientists and researchers to delve deeper into understanding cellular mechanisms, refining manufacturing techniques, and developing novel therapies. This acceleration of scientific discovery forms the cornerstone of growth in the cell therapy manufacturing market.

Effective translation of research findings from the laboratory to practical applications is a critical aspect of cell therapy development. Robust R&D investments in France bridge this gap, facilitating the seamless transition of promising therapies from the bench to the bedside. This translational approach ensures that groundbreaking discoveries are swiftly transformed into viable and marketable cell therapies.

R&D investments stimulate innovation by providing the necessary resources for exploring novel therapeutic approaches. In France, a thriving ecosystem of collaboration between academic institutions, research organizations, and industry players is catalyzing the development of innovative cell therapies. These investments are nurturing a culture of innovation that propels the growth of the cell therapy manufacturing market.

Advancing cell therapies from the laboratory to clinical trials requires substantial financial support. R&D investments in France play a pivotal role in supporting these critical phases of development. Funding for clinical trials ensures that cell therapies undergo rigorous testing for safety and efficacy, paving the way for regulatory approvals. This support is instrumental in bringing new therapies to market and fostering confidence among stakeholders.

R&D investments contribute to the establishment of state-of-the-art infrastructure and manufacturing capabilities in France. Cutting-edge facilities equipped with the latest technologies enable efficient and scalable production of cell therapies. These investments in manufacturing capabilities position France as a hub for cell therapy production, attracting further investments and fostering growth in the market.

#### Increasing Demand for Personalized Medicine

The paradigm shift toward personalized medicine has revolutionized the healthcare landscape, and France is at the forefront of this transformative journey. Within the heart of this evolution lies the cell therapy manufacturing market, witnessing substantial growth driven by the increasing demand for personalized medicine.

The demand for personalized medicine arises from a desire to move away from one-size-fits-all treatments toward more precise

and targeted therapeutic approaches. Cell therapies, being inherently adaptable, align seamlessly with the principles of personalized medicine. In France, this alignment is driving innovation in the cell therapy manufacturing sector, as therapies are tailored to address individual patient profiles with a level of precision previously unseen.

The surge in demand for personalized medicine is diversifying the applications of cell therapies across various diseases. Whether addressing cancers, autoimmune disorders, or degenerative conditions, the adaptability of cell therapies allows for customization to match the specific characteristics of each patient's illness. In France, this broadening scope is fostering a comprehensive approach to personalized healthcare, propelling the growth of the cell therapy manufacturing market.

The demand for personalized medicine acts as a catalyst for increased investment in research and development (R&D) within France's cell therapy manufacturing sector. The need to develop specific and targeted treatments fuels a continuous cycle of innovation, leading to the discovery of novel cell therapies tailored to unique patient profiles. The interplay between personalized medicine and R&D investments is propelling France to the forefront of cell therapy development.

In an era where patients are increasingly seeking personalized treatment options, cell therapies offer a promising solution. Patients are more likely to engage with and benefit from treatments that align with their unique genetic makeup and health conditions. The demand for personalized medicine, therefore, acts as a driver for the adoption of cell therapies, boosting patient satisfaction and outcomes.

#### Global Competitiveness

As the field of healthcare undergoes a paradigm shift towards advanced and personalized treatments, the global competitiveness of nations plays a crucial role in shaping their position in this transformative landscape. France, with its commitment to innovation and technological prowess, is leveraging global competitiveness to drive growth in its cell therapy manufacturing market.

Global competitiveness in cell therapy manufacturing requires active collaboration and knowledge exchange with international partners. France, with its open and collaborative approach, fosters relationships with researchers, companies, and institutions worldwide. This exchange of expertise accelerates the pace of innovation, ensuring that France remains at the cutting edge of advancements in cell therapy technologies.

A competitive environment attracts top-tier talent from around the world. France's cell therapy manufacturing market benefits from a diverse pool of scientists, researchers, and industry experts who contribute their unique perspectives and skills. This infusion of global talent enhances the nation's capability to address complex challenges and drive innovation in the development and manufacturing of cell therapies.

To compete on the global stage, adherence to international quality standards is paramount. France's commitment to maintaining high-quality standards in cell therapy manufacturing ensures that its products meet or exceed global expectations. This commitment enhances the competitiveness of French cell therapies in international markets, fostering trust and confidence among stakeholders.

Global competitiveness thrives on strategic collaborations and partnerships. French companies engaged in cell therapy manufacturing actively seek collaborations with international counterparts, leveraging complementary strengths. These partnerships not only facilitate the exchange of knowledge but also open doors to new markets, expanding the reach of French cell therapies on a global scale.

Remaining globally competitive necessitates a continuous focus on technological innovation and infrastructure development. France's investment in cutting-edge technologies and state-of-the-art manufacturing facilities positions the nation as a leader in the global cell therapy manufacturing market. Advanced infrastructure enables efficient, scalable, and cost-effective production, giving French companies a competitive edge.

#### Key Market Challenges

##### Complex Production Processes

Cell therapy manufacturing involves intricate and highly sensitive production processes. The complexity arises from the need to handle living cells, which are fragile and can be affected by various factors such as temperature, nutrient levels, and contamination. Ensuring consistency and scalability in these processes presents a significant challenge for manufacturers in France.

##### Skilled Workforce Shortage

The specialized nature of cell therapy manufacturing demands a highly skilled workforce. France, like many other countries, faces

a shortage of professionals with the expertise required for the development and production of cell therapies. Training programs and educational initiatives must be expanded to address this workforce gap and ensure the industry has the talent it needs to thrive.

#### Costs and Economic Viability

The production of cell therapies can be expensive due to the need for advanced technologies, stringent quality control measures, and complex manufacturing processes. Balancing the economic viability of cell therapy manufacturing while ensuring access to these therapies for a broad patient population remains a significant challenge. Cost-effective approaches must be explored without compromising the quality and safety of the final products.

#### Key Market Trends

##### Expansion of Indications and Therapeutic Areas

One of the notable trends in France's cell therapy manufacturing market is the expansion of indications and therapeutic areas. While initially focused on areas like oncology, there is a growing exploration of cell therapies for a broader range of diseases, including autoimmune disorders, neurodegenerative conditions, and cardiovascular diseases. This trend signifies a shift toward more diverse and personalized treatment options.

##### Next-Generation Manufacturing Technologies

The adoption of next-generation manufacturing technologies is poised to revolutionize the efficiency and scalability of cell therapy production in France. Innovations such as advanced bioreactor systems, automation, and closed-system processing are becoming increasingly prevalent. These technologies not only streamline production processes but also address challenges related to consistency, cost-effectiveness, and large-scale manufacturing.

##### Gene-Editing Techniques and Advanced Genetic Therapies

Advancements in gene-editing techniques, including CRISPR-Cas9, are opening new possibilities for cell therapy manufacturing in France. The ability to precisely modify the genetic makeup of cells enhances therapeutic efficacy, offering more targeted and personalized treatment options. The integration of advanced genetic therapies into cell therapy manufacturing is expected to be a transformative trend in the coming years.

#### Segmental Insights

##### Therapy Insights

Based on Therapy, Stem cell therapies are poised to dominate the Cell Therapy Manufacturing Market in France due to their unparalleled potential in revolutionizing medical treatments. The versatility of stem cells allows for their differentiation into various cell types, offering a promising avenue for addressing a myriad of health conditions. This adaptability is especially crucial in France, where a growing aging population is facing an increasing burden of degenerative diseases. Stem cell therapies exhibit remarkable regenerative capabilities, presenting a unique solution for treating conditions ranging from neurodegenerative disorders to cardiovascular diseases. Moreover, the advancements in cell therapy manufacturing technologies have enhanced scalability, ensuring cost-effective and efficient production. As France continues to prioritize innovation in healthcare, the emphasis on personalized medicine and regenerative therapies aligns seamlessly with the attributes of stem cell treatments, making them the frontrunners in shaping the future of the French Cell Therapy Manufacturing Market.

##### Application Insights

Based on Application, Oncology is poised to dominate the Cell Therapy Manufacturing Market in France, driven by the pressing need for advanced and effective treatments in the fight against cancer. The rising incidence of various forms of cancer in the country has intensified the demand for innovative therapeutic solutions, and cell therapies, particularly those focusing on oncological applications, have emerged as a beacon of hope. The personalized nature of cell therapies enables tailored treatments, targeting specific cancer types and individual patient profiles, leading to enhanced efficacy and reduced side effects compared to conventional treatments. France's robust healthcare infrastructure and commitment to cutting-edge medical technologies create a conducive environment for the rapid integration of cell therapy manufacturing, especially in the oncology space. As research and development efforts continue to flourish, the convergence of scientific advancements and market dynamics positions oncology as the dominant application within the burgeoning landscape of the French Cell Therapy Manufacturing Market.

##### Regional Insights

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Northern France is poised to dominate the Cell Therapy Manufacturing Market in France, driven by a strategic confluence of factors that position the region as a hub for cutting-edge biotechnology and pharmaceutical innovation. The region boasts a well-established infrastructure with world-class research and development facilities, fostering collaboration between academia and industry. Moreover, Northern France's strategic geographic location facilitates seamless connectivity and logistics, ensuring efficient supply chains critical for cell therapy manufacturing. The presence of skilled talent, a robust regulatory framework, and proactive government support further contribute to the region's prominence in the field. As the demand for cell therapies continues to escalate, Northern France's commitment to fostering a conducive business environment and its focus on technological advancements make it a frontrunner in shaping the landscape of the French Cell Therapy Manufacturing Market.

#### Key Market Players

Novartis AG  
Roche SAS  
Gilead Sciences, Inc  
Catalent, Inc  
Cell and Gene Therapy Catapult  
Merck KGaA  
Lonza France  
Charles River Laboratories  
Institut Merieux (ABL Inc.)  
Amgen

#### Report Scope:

In this report, the France Cell Therapy Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

##### □□France Cell Therapy Manufacturing Market, By Therapy:

- o□T-Cell Therapies
- o□Dendritic Cell Therapies
- o□Tumor Cell Therapies
- o□Stem Cell Therapies

##### □□France Cell Therapy Manufacturing Market, By Source of Cell:

- o□Autologous
- o□Allogenic

##### □□France Cell Therapy Manufacturing Market, By Scale of Operation:

- o□Preclinical
- o□Clinical
- o□Commercial

##### □□France Cell Therapy Manufacturing Market, By Source:

- o□In-House
- o□Contract Manufacturing

##### □□France Cell Therapy Manufacturing Market, By Application:

- o□Oncology
- o□Cardiovascular Diseases
- o□Orthopedic Diseases
- o□Others

##### □□France Cell Therapy Manufacturing Market, By End User:

- o□Pharmaceutical & Biotechnology Companies
- o□Academic & Research Institutes
- o□Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

□□France Cell Therapy Manufacturing Market, By Region:

o□Northern France

o□Southern France

o□Western France

o□Central France

o□Eastern France

o□Southwestern France

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the France Cell Therapy Manufacturing Market.

Available Customizations:

France Cell Therapy Manufacturing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

□□Detailed analysis and profiling of additional market players (up to five).

## **Table of Contents:**

1.□Service Overview

1.1.□Market Definition

1.2.□Scope of the Market

1.2.1.□Markets Covered

1.2.2.□Years Considered for Study

1.2.3.□Key Market Segmentations

2.□Research Methodology

2.1.□Objective of the Study

2.2.□Baseline Methodology

2.3.□Key Industry Partners

2.4.□Major Association and Secondary Sources

2.5.□Forecasting Methodology

2.6.□Data Triangulation & Validation

2.7.□Assumptions and Limitations

3.□Executive Summary

3.1.□Overview of the Market

3.2.□Overview of Key Market Segmentations

3.3.□Overview of Key Market Players

3.4.□Overview of Key Regions/Countries

3.5.□Overview of Market Drivers, Challenges, Trends

4.□Voice of Customer

5.□France Cell Therapy Manufacturing Market Outlook

5.1.□Market Size & Forecast

5.1.1.□By Value

5.2.□Market Share & Forecast

5.2.1.□By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)

5.2.2.□By Source of Cell (Autologous, Allogenic)

5.2.3.□By Scale of Operation (Preclinical, Clinical, Commercial)

5.2.4.□By Source (In-House, Contract Manufacturing)

5.2.5.□By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)

5.2.6.□By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.7. By Region
- 5.2.8. By Company (2022)
- 5.3. Market Map
- 5.3.1. By Therapy
- 5.3.2. By Source of Cell
- 5.3.3. By Scale of Operation
- 5.3.4. By Source
- 5.3.5. By Application
- 5.3.6. By End User
- 5.3.7. By Region
- 6. Northern France Cell Therapy Manufacturing Market Outlook
  - 6.1. Market Size & Forecast
    - 6.1.1. By Value
  - 6.2. Market Share & Forecast
    - 6.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
    - 6.2.2. By Source of Cell (Autologous, Allogenic)
    - 6.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
    - 6.2.4. By Source (In-House, Contract Manufacturing)
    - 6.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
    - 6.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 7. Southern France Cell Therapy Manufacturing Market Outlook
  - 7.1. Market Size & Forecast
    - 7.1.1. By Value
  - 7.2. Market Share & Forecast
    - 7.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
    - 7.2.2. By Source of Cell (Autologous, Allogenic)
    - 7.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
    - 7.2.4. By Source (In-House, Contract Manufacturing)
    - 7.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
    - 7.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 8. Western France Cell Therapy Manufacturing Market Outlook
  - 8.1. Market Size & Forecast
    - 8.1.1. By Value
  - 8.2. Market Share & Forecast
    - 8.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
    - 8.2.2. By Source of Cell (Autologous, Allogenic)
    - 8.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
    - 8.2.4. By Source (In-House, Contract Manufacturing)
    - 8.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
    - 8.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 9. Central France Cell Therapy Manufacturing Market Outlook
  - 9.1. Market Size & Forecast
    - 9.1.1. By Value
  - 9.2. Market Share & Forecast
    - 9.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
    - 9.2.2. By Source of Cell (Autologous, Allogenic)
    - 9.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2.4.□By Source (In-House, Contract Manufacturing)
- 9.2.5.□By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
- 9.2.6.□By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 10.□Eastern France Cell Therapy Manufacturing Market Outlook
- 10.1.□Market Size & Forecast□
- 10.1.1.□By Value
- 10.2.□Market Share & Forecast
- 10.2.1.□By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
- 10.2.2.□By Source of Cell (Autologous, Allogenic)
- 10.2.3.□By Scale of Operation (Preclinical, Clinical, Commercial)
- 10.2.4.□By Source (In-House, Contract Manufacturing)
- 10.2.5.□By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
- 10.2.6.□By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 11.□Southwestern France Cell Therapy Manufacturing Market Outlook
- 11.1.□Market Size & Forecast□
- 11.1.1.□By Value
- 11.2.□Market Share & Forecast
- 11.2.1.□By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
- 11.2.2.□By Source of Cell (Autologous, Allogenic)
- 11.2.3.□By Scale of Operation (Preclinical, Clinical, Commercial)
- 11.2.4.□By Source (In-House, Contract Manufacturing)
- 11.2.5.□By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
- 11.2.6.□By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 12.□Market Dynamics
- 12.1.□Drivers
- 12.2.□Challenges
- 13.□Market Trends & Developments
- 13.1.□Recent Developments
- 13.2.□Mergers & Acquisitions
- 13.3.□Product Launches
- 14.□Policy & Regulatory Landscape
- 15.□Porter's Five Forces Analysis
- 15.1.□Competition in the Industry
- 15.2.□Potential of New Entrants
- 15.3.□Power of Suppliers
- 15.4.□Power of Customers
- 15.5.□Threat of Substitute Products
- 16.□France Economic Profile
- 17.□Competitive Landscape
- 17.1.□Business Overview
- 17.2.□Product Offerings
- 17.3.□Recent Developments
- 17.4.□Financials (As Reported)
- 17.5.□Key Personnel
- 17.6.□SWOT Analysis
- 17.6.1.□Novartis AG
- 17.6.2.□Roche SAS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 17.6.3. □ Gilead Sciences, Inc
- 17.6.4. □ Catalent, Inc
- 17.6.5. □ Cell and Gene Therapy Catapult
- 17.6.6. □ Merck KGaA
- 17.6.7. □ Lonza France
- 17.6.8. □ Charles River Laboratories
- 17.6.9. □ Institut Merieux (ABL Inc.)
- 17.6.10. □ Amgen
- 18. □ Strategic Recommendations

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**France Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous, Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House, Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F**

Market Report | 2023-11-07 | 78 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email\*

Phone\*

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-04"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)